|
Market Closed -
Xetra
12:35:24 2026-10-28 EDT
|
After hours 15:42:21 | |||
| 19.16 EUR | +1.48% |
|
19.23 | +0.37% |
| 10-26 | Formycon AG : Berenberg gives a Buy rating | ZD |
| 10-21 | Formycon Partners with Biocelys to Develop Biosimilar Candidate | MT |
Company Valuation: Formycon AG
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 651.7 | 1,309 | 904.6 | 937.6 | 452.2 | 333.7 | - | - |
| Change | - | 100.81% | -30.88% | 3.65% | -51.77% | -26.21% | - | - |
| Enterprise Value (EV) 1 | 626.6 | 1,648 | 907.1 | 906.3 | 392.9 | 447.9 | 447.1 | 401 |
| Change | - | 162.95% | -44.94% | -0.08% | -56.65% | 13.98% | -0.18% | -10.31% |
| P/E | -48.4x | 33.4x | 11.9x | -7.4x | -6.99x | 581x | 14.3x | 16.6x |
| PBR | 11.6x | 3.67x | 1.8x | 2.03x | 1.13x | 0.86x | 0.91x | 0.86x |
| PEG | - | -0x | 0.1x | 0x | 0.1x | -6x | 0x | -1.2x |
| Capitalization / Revenue | 17.6x | 30.8x | 11.6x | 13.5x | 10.2x | 4.59x | 2.98x | 3.4x |
| EV / Revenue | 17x | 38.8x | 11.7x | 13x | 8.83x | 6.16x | 3.99x | 4.09x |
| EV / EBITDA | -50.6x | -104x | 598x | -66x | -110x | -93.2x | 8.38x | 7.16x |
| EV / EBIT | -47x | -92.9x | -2,458x | -38.5x | -12.9x | -34.6x | 17.7x | 12.9x |
| EV / FCF | -42.1x | -36.1x | -29.2x | -17x | -8.91x | -12.5x | 112x | 34.8x |
| FCF Yield | -2.38% | -2.77% | -3.42% | -5.87% | -11.2% | -7.97% | 0.89% | 2.88% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.218 | 2.59 | 4.72 | -7.18 | -3.66 | 0.0325 | 1.324 | 1.14 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 36.96 | 42.5 | 77.7 | 69.67 | 44.48 | 72.66 | 112 | 98 |
| EBITDA 1 | -12.39 | -15.87 | 1.518 | -13.74 | -3.571 | -4.808 | 53.33 | 56 |
| EBIT 1 | -13.33 | -17.73 | -0.369 | -23.54 | -30.5 | -12.94 | 25.29 | 31.1 |
| Net income 1 | -13.48 | 35.99 | 75.8 | -125.7 | -64.7 | 0.593 | 23.19 | 20 |
| Net Debt 1 | -25.18 | 338.8 | 2.501 | -31.24 | -59.28 | 114.2 | 113.4 | 67.3 |
| Reference price 2 | 59.00 | 86.50 | 56.40 | 53.10 | 25.60 | 18.88 | 18.88 | 18.88 |
| Nbr of stocks (in thousands) | 11,047 | 15,130 | 16,039 | 17,657 | 17,664 | 17,673 | - | - |
| Announcement Date | 5/18/22 | 4/27/23 | 4/25/24 | 3/27/25 | 4/22/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 580.92x | 6.16x | -93.15x | -.--% | 372M | |
| 17.08x | 6.33x | 12.4x | 1.75% | 63.48B | |
| 30.03x | 7.96x | 26.08x | 0.05% | 54.55B | |
| 37.03x | 6.57x | 19.63x | 0.87% | 53.59B | |
| 35.05x | 3.37x | 14.55x | -.--% | 44.75B | |
| 48.28x | 5.55x | 30.42x | -.--% | 41.62B | |
| -19.33x | 186.93x | -20.57x | -.--% | 39.91B | |
| 30.28x | 7.94x | 20.6x | 0.4% | 32.47B | |
| 36.51x | 6.64x | 22.27x | -.--% | 26.7B | |
| 26.96x | 5.67x | 14.71x | -.--% | 23.36B | |
| Average | 82.28x | 24.31x | 4.69x | 0.31% | 38.08B | |
| Weighted average by Cap. | 27.09x | 25.21x | 15.57x | 0.46% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- FYB Stock
- Valuation Formycon AG
Select your edition
All financial news and data tailored to specific country editions
